ElagoliX is a treatment that is under development to treat people suffering from uterine endometriosis and leiomyoma, in addition its experimental phase also seeks to treat patients with prostate cancer and benign prostatic hyperplasia. Studies to launch this drug on the market are not yet available, since it has not yet been able to inhibit some side effects that could seriously affect the patient.
The results obtained after various studies showed that less than half of the patients who were given egolix reacted positively to the treatment, so it is still being studied to improve the success rate
The most common side effects that egolix can cause are headache, diarrhea, nausea and vomiting, jaw pain, myalgia (muscle pain), limb pain, arthralgia (joint pain), and flushing. These effects are mild or moderate and are seen more frequently while the dose is being increased, although this usually happens to one in ten patients.
Egolix is expected to be presented in tablets of 200, up to 1,400 and 1,600 micrograms. Treatment should be started depending on the doctor's instructions, although for greater effect a dose of 200 micrograms twice a day is expected, approximately 12 hours apart. The dose is then increased weekly, as long as it is tolerated, to a maximum of 1,600 micrograms twice daily. Patients can better tolerate the treatment if they take their pills with food and take the first tablet of an increased dose in the evening rather than in the morning. If the patient cannot tolerate an increase in the dose, the doctor may have to reduce it.
